Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55

Benzinga · 2d ago
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.